CD8⁺ cytotoxic T cell and FOXP3⁺ regulatory T cell infiltration in relation to breast cancer survival and molecular subtypes
- PMID: 21717105
- DOI: 10.1007/s10549-011-1647-3
CD8⁺ cytotoxic T cell and FOXP3⁺ regulatory T cell infiltration in relation to breast cancer survival and molecular subtypes
Abstract
The prognostic significance of tumor-associated FOXP3(+) regulatory T cells (Tregs) and CD8(+) cytotoxic T lymphocytes (CTLs) in invasive breast carcinomas is studied. Tregs and CTLs were assessed by immunohistochemistry in 1270 cases of invasive breast carcinoma for their associations with patient survival, histopathologic features, and molecular subtypes. Infiltrates of Tregs and CTLs were observed within tumor bed and in the tissue surrounding tumor. Within tumor bed, increased infiltration of Tregs and CTLs was significantly more common in those with unfavorable histologic features, including high histologic grade and negative ER and PR status. In addition, high density Treg infiltration was also associated with tumor HER2 overexpression, decreased overall survival (OS) and progression-free survival (PFS). In tissue surrounding tumor, in contrast, high CTL/Treg ratio was found to be significantly associated with improved OS and PFS. These prognostic associations were confirmed by multivariate analysis. Furthermore, the density of Treg infiltrates within tumors was inversely correlated with the prognosis of the molecular subtypes of tumors. The ratio of CTL/Treg infiltrates in the surrounding tissue was also significantly higher in luminal than non-luminal subtypes of carcinoma. The prognostic significances of Tregs and CTLs in breast carcinoma depend on their relative density and location. The density of intratumoral Treg infiltrates and the peritumoral CTL/Treg ratio are independent prognostic factors and correlated with the prognosis of the molecular subtypes of breast carcinoma, which may serve as potential target for stratifying immunotherapy to battle against the aggressive subtypes of breast carcinoma.
Similar articles
-
Peritumoral FOXP3⁺ regulatory T cell is sensitive to chemotherapy while intratumoral FOXP3⁺ regulatory T cell is prognostic predictor of breast cancer patients.Breast Cancer Res Treat. 2012 Sep;135(2):459-67. doi: 10.1007/s10549-012-2132-3. Epub 2012 Jul 29. Breast Cancer Res Treat. 2012. PMID: 22842982
-
Tumor-infiltrating lymphocytes, tumor characteristics, and recurrence in patients with early breast cancer.Am J Clin Oncol. 2013 Jun;36(3):224-31. doi: 10.1097/COC.0b013e3182467d90. Am J Clin Oncol. 2013. PMID: 22495453
-
Tumor-infiltrating FoxP3+ Tregs and CD8+ T cells affect the prognosis of hepatocellular carcinoma patients.Digestion. 2012;86(4):329-37. doi: 10.1159/000342801. Epub 2012 Nov 28. Digestion. 2012. PMID: 23207161
-
Regulatory T cells are an important prognostic factor in breast cancer: a systematic review and meta-analysis.Neoplasma. 2016;63(5):789-98. doi: 10.4149/neo_2016_517. Neoplasma. 2016. PMID: 27468884
-
FOXP3 regulatory T cells on prognosis of breast cancer.Breast Dis. 2023;42(1):213-218. doi: 10.3233/BD-239002. Breast Dis. 2023. PMID: 37458005 Review.
Cited by
-
Host response in tumor diagnosis and prognosis: importance of immunologists and pathologists alliance.Exp Mol Pathol. 2012 Dec;93(3):315-8. doi: 10.1016/j.yexmp.2012.10.013. Epub 2012 Oct 23. Exp Mol Pathol. 2012. PMID: 23099314 Free PMC article. Review.
-
CD39 is highly involved in mediating the suppression activity of tumor-infiltrating CD8+ T regulatory lymphocytes.Cancer Immunol Immunother. 2013 May;62(5):851-62. doi: 10.1007/s00262-013-1392-z. Epub 2013 Jan 29. Cancer Immunol Immunother. 2013. PMID: 23359087 Free PMC article.
-
Current Issues and Clinical Evidence in Tumor-Infiltrating Lymphocytes in Breast Cancer.J Pathol Transl Med. 2015 Sep;49(5):355-63. doi: 10.4132/jptm.2015.07.29. Epub 2015 Aug 17. J Pathol Transl Med. 2015. PMID: 26278518 Free PMC article. Review.
-
A comprehensive information database (CID) of breast cancer patients in China.Front Med. 2012 Jun;6(2):212-6. doi: 10.1007/s11684-012-0185-7. Epub 2012 May 8. Front Med. 2012. PMID: 22570128 No abstract available.
-
Harnessing DNA Repair Defects to Augment Immune-Based Therapies in Triple-Negative Breast Cancer.Front Oncol. 2021 Sep 24;11:703802. doi: 10.3389/fonc.2021.703802. eCollection 2021. Front Oncol. 2021. PMID: 34631532 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous